Trials Sponsors Conditions Drugs Pricing

Conditions

Diabetic Retinopathy Macular Traction Retinal Detachment

Keywords

tranexamic aciddiabetes mellitusmacular TRD

Outcome Measures

Primary Outcomes (1)

Number of systemic adverse events
Safety of intravenous tranexamic acid
intraoperatively and postoperatively 24 hours

Secondary Outcomes (9)

Number of systemic adverse events in patients having Chronic kidney disease
intraoperatively and postoperatively 24 hours
Surgical time for vitrectomy
intraoperatively
Any relation between intraoperative use of Tranexamic acid and labetalol
intraoperatively
Number of vitrectomies converted intraoperatively to bimanual technique
intraoperatively
Number of surgeries in which retinectomy required
intraoperatively
+4 more secondary outcomes

Eligibility Criteria

Age18 Years - 99 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

diabetic patients having Macular tractional retinal detachment who visited Retina department, Ahalia foundation eye hospital, palakkad, underwent surgery and gave informed written consent to be included in study

You may qualify if:

Eyes of Diabetic patients having Macular Tractional Retinal detachment confirmed on Indirect Ophthalmoscope or B scan when associated with Vitreous hemorrhage or Optical Coherence Tomography

Sponsors & Collaborators

Ahalia Foundation Eye Hospital
Otherlead

Study Sites (1)

Ahaliafoundation Eye Hospital

Palakkad, Kerala, 678557, India

MeSH Terms

Conditions

Diabetic RetinopathyDiabetes Mellitus

Condition Hierarchy (Ancestors)

Retinal DiseasesEye DiseasesDiabetic AngiopathiesVascular DiseasesCardiovascular DiseasesDiabetes ComplicationsEndocrine System DiseasesGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

RAJKUMAR MAHESHWARI, MS
Ahalia Foundation Eye Hospital
STUDY DIRECTOR
SAURAV MAHAJAN, MS
Ahalia Foundation Eye Hospital
PRINCIPAL INVESTIGATOR
AANCHAL MAINGI, DNB
AHALIA DIABETES HOSPITAL
PRINCIPAL INVESTIGATOR

Enrollment

102 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Director Retina

Study Record Dates

First Submitted

August 15, 2024

First Posted

August 19, 2024

Study Start

January 15, 2021

Actual (reported)

Intravenous Tranexamic Acid in Diabetic Macular TRD Surgeries

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (9)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (9)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations